A A A Text Size
SPRING 2011 Newsletter the villager newsletter Providing information and inspiration to the hemophilia community.

Q&A: TEACHING YOUR SON TO SELF-INFUSE

Self-infusing works around your needs and your schedule.

Q: How old is your son?

A: Kevin is now 19.

Q: When did you teach him to self-infuse?

A: When he was in 6th grade, he and his brother both decided they were ready to start infusing themselves. The Home Health nurse is the one who taught Kevin—at his request! One visit and that was it.

Q: So Kevin did not learn to infuse at camp?

A: No, but helping to teach other kids to infuse at camp is a source of great happiness since he could relate to the younger kids.

Q: Do you think there's any right or best time to teach self-infusion?

A: Every child is unique with different family dynamics and support systems.

Q: What did you most hope to accomplish in teaching your son to self-infuse?

A: To try and help him become independent—kids have to learn it's their condition and they are ultimately responsible. A parent's role is to help the child get ready. We don't want to keep them dependent.

Q: Do you believe kids who have hemophilia want to keep up with their friends/peers who self-infuse?

A: At home or at school, not really; because there are so few kids who have hemophilia that they might come into contact with. But at camp, yes, that's another story—there is "good" pressure to learn to infuse.

Q: Is there any other benefit to encouraging or teaching your child to self-infuse?

A: Absolutely. Because Kevin self-infuses on demand, he would infuse at the right time rather than wait for someone else to do it—infusing sooner than later. Infusing when they need to can give them freedom to do the things they want to do and not interfere as much with their active lifestyle.

Learn more at BeneFIX.com.

What Is BeneFIX?

BeneFIX® Coagulation Factor IX (Recombinant) is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease.

BeneFIX is NOT used to treat hemophilia A.

Important Safety Information for BeneFIX

  • BeneFIX is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein.
  • Call your health care provider right away if your bleeding is not controlled after using BeneFIX.
  • Allergic reactions may occur with BeneFIX. Call your health care provider or get emergency treatment right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, your lips and gums turning blue, fast heartbeat, facial swelling, faintness, rash or hives.
  • Your body can make antibodies, called “inhibitors,” which may interfere with the effectiveness of BeneFIX.
  • If you have risk factors for developing blood clots, such as a venous catheter through which BeneFIX is given by continuous infusion, BeneFIX may increase the risk of abnormal blood clots. The safety and efficacy of BeneFIX administration by continuous infusion have not been established.
  • Some common side effects of BeneFIX are nausea, injection site reaction, injection site pain, headache, dizziness and rash.

Please see full Prescribing Information for BeneFIX.

What Is XYNTHA?

Xyntha® Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is indicated for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

XYNTHA does not contain von Willebrand factor and, therefore, is not indicated in von Willebrand's disease.

Important Safety Information for XYNTHA

  • Allergic reactions are possible with XYNTHA. Signs of an allergic reaction may include hives, rash with itching, chest tightness, difficulty breathing, faintness, or fast heartbeat. XYNTHA contains trace amounts of hamster protein. You may develop an allergic reaction to these proteins. Tell your doctor if you have had an allergic reaction to hamster protein.
  • Call your doctor right away if bleeding is not controlled after using your factor VIII replacement therapy; this may be a sign of an inhibitor. Inhibitors have been observed in patients receiving factor VIII products, including XYNTHA.
  • The most common adverse reaction in study 1 (safety and efficacy study) is headache (24% of subjects) and in study 2 (surgery study) is fever (41% of subjects). Other common side effects of XYNTHA include nausea, vomiting, diarrhea, or weakness.
  • XYNTHA is an injectable medicine administered by intravenous (IV) infusion. Local irritation may occur when infusing XYNTHA after reconstitution in XYNTHA Solofuse.

Please see full Prescribing Information for XYNTHA.

RUS277708-01

Quick Poll

Did you ever attend hemophilia camp?


Submit your details

Your Results

 
 
 
 
Registration

Error 404

Cancel X Hemophilia Village
Submit >